News


All series


All News

According to findings reported during the 2018 Gastrointestinal Cancers Symposium, a weekly dose-escalation strategy of regorafenib (Stivarga) beginning at 80 mg and ending at 160 mg was found to be superior than the previously standard starting dose of 160 mg in patients with metastatic colorectal cancer.

Based on findings from the&nbsp;ALCYONE study,&nbsp;which were published in the <em>New England Journal of Medicine</em> and presented at the 2017 ASH Annual Meeting,<sup>&nbsp;</sup>the FDA has granted a priority review designation to&nbsp;daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Madappa Kundranda, MD, PhD, recently discussed the cases of 2 patients with hepatocellular carcinoma (HCC), and the treatment considerations and decisions he would make when treating these patients. Dr. Kundranda, Director of Gastrointestinal Oncology at Banner MD Anderson Cancer Center, Phoenix discussed these cases during a <em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

A novel circulating tumor cell assay has demonstrated a high accuracy of up to 88% for detecting early-stage colorectal cancer, according to the results of a prospective study from Taiwan released ahead of a presentation at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California. The study marks the first to show a high sensitivity for detecting precancerous lesions, as prior studies tended to identify later-stage CRCs.

Based on results of the phase II JULIET study,&nbsp;a supplemental biologics license application for the CAR T-cell therapy tisagenlecleucel (Kymriah) has been granted a priority review by the FDA&nbsp;as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for or relapse after autologous stem cell transplant.

Mary C. Beckerle, PhD, has been awarded the Alfred G. Knudson Award in Cancer Genetics by the National Cancer Institute (NCI). She received her award at the NCI&rsquo;s Maryland headquarters before delivering a lecture on tumor biology.

Arsenic trioxide (Trisenox) has been approved by the FDA in&nbsp;combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or <em>PML-RARA</em> gene expression.

The frontline indication for afatinib (Gilotrif) has been expanded by the FDA to include&nbsp;the treatment of patients with metastatic non&ndash;small cell lung cancer whose tumors harbor uncommon <em>EGFR</em> alterations in L861Q, G719X, and/or S768I.

C. Ola Landgren, MD, PhD, recently shared the treatment considerations and decisions he makes when treating patients with multiple myeloma. Landgren, chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center, in New York, explained his treatment decisions based on 2 case scenarios during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

Prachi Mishra, PhD, was awarded the first &ldquo;Colonel (Ret.) David G. McLeod Prostate Cancer Translational Research Fellowship&rdquo; at the Uniformed Services University of Health Sciences on December 7. She was presented this award in front of Department of Defense leadership, industry leaders, cancer scientists, military healthcare providers, and other colleagues.

According to findings from the phase III TERRA trial published in the <em>Journal of Clinical Oncology, </em>previously treated Asian patients with metastatic colorectal cancer saw a significant survival benefit with TAS-102&nbsp;(trifluridine and tipiracil; Lonsurf) compared with placebo.